Travere Therapeutics (TVTX) Tops Q4 EPS by 31c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Travere Therapeutics (TVTX) PT Raised to $61 at Wedbush
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks